Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p48
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 48/191)
Character Range: 10020167–10032834

(PCR)] is desirable but need not delay treatment.
C5937               P5937          CN5937           Famciclovir                                                                                                                                                                Recurrent moderate to severe genital herpes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 5937
                                                                                                                                                                                                                               Episodic treatment
                                                                                                                                                                                                                               Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desirable but need not delay treatment.
C5938               P5938          CN5938           Folinic acid                                                                                                                                                               Megaloblastic anaemias
                                                                                                                                                                                                                               The condition must be a result of folic acid deficiency from the use of folic acid antagonists.
C5940               P5940          CN5940           Valaciclovir                                                                                                                                                               Recurrent moderate to severe genital herpes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 5940
                                                                                                                                                                                                                               Suppressive therapy
                                                                                                                                                                                                                               Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desirable but need not delay treatment.
C5941               P5941          CN5941           Nitrazepam                                                                                                                                                                 Insomnia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Compliance with Authority Required procedures
                                                                                                                                                                                                                               Patient must be receiving this drug for the management of insomnia; AND
                                                    Temazepam                                                                                                                                                                  Patient must be receiving long-term nursing care; AND
                                                                                                                                                                                                                               Patient must be one in respect of whom a Carer Allowance is payable as a disabled adult; AND
                                                                                                                                                                                                                               Patient must have demonstrated, within the past 6 months, benzodiazepine dependence by an unsuccessful attempt at gradual withdrawal.
C5942               P5942          CN5942           Aciclovir                                                                                                                                                                  Recurrent moderate to severe genital herpes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 5942
                                                                                                                                                                                                                               Episodic treatment or suppressive therapy
                                                                                                                                                                                                                               Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desirable but need not delay treatment.
C5943               P5943          CN5943           Famciclovir                                                                                                                                                                Herpes zoster                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 5943
                                                                                                                                                                                                                               Patient must be immunocompromised; AND
                                                                                                                                                                                                                               The treatment must be administered within 72 hours of the onset of the rash.
C5945               P5945          CN5945           Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides                                                               Eosinophilic oesophagitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures
                                                                                                                                                                                                                               Initial treatment for up to 3 months
                                                    Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides                                                       Must be treated by a clinical immunologist, suitably qualified allergist or gastroenterologist; AND
                                                                                                                                                                                                                               Patient must require an amino acid based formula as a component of a dietary elimination program;
                                                                                                                                                                                                                               Patient must be 18 years of age or less.
                                                                                                                                                                                                                               Treatment with oral steroids should not be commenced during the period of initial treatment.
                                                                                                                                                                                                                               Eosinophilic oesophagitis is demonstrated by the following criteria
                                                                                                                                                                                                                               (i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and
                                                                                                                                                                                                                               (ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and
                                                                                                                                                                                                                               (iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any